Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of metronomic oral
vinorelbine taken three times a week plus daily lapatinib without break, as salvage treatment
in patients with metastatic breast cancer.